Use of an RNA-based HRD signature significantly expands the fraction of patients with prostate cancer who may derive benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) compared with using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback